Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.

Slides:



Advertisements
Similar presentations
Volume 15, Issue 8, Pages (December 2012)
Advertisements

Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results  Becky Pennington, MSc,
Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Volume 17, Issue 8, Pages (December 2014)
Volume 15, Issue 2, Pages (March 2012)
Volume 14, Issue 8, Pages (December 2011)
Volume 17, Issue 2, Pages (March 2014)
Value in Health Regional Issues
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
Value in Health Regional Issues
Value in Health Regional Issues
Value in Health Regional Issues
Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.
Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation.
Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?  Emmanuel Ankrah Odame, MBCHB, MPH  Value in.
Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making 
Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil  Ronaldo K.
Value in Health Regional Issues
Value in Health Regional Issues
Cost-Effectiveness Analysis of Everolimus versus Mycophenolate in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis for Cytomegalovirus.
Ernest Attuquaye Quaye, BPharm, MPH, Edward O
Value in Health Regional Issues
Value in Health Regional Issues
Radiology Services Costs and Utilization Patterns Estimates in Southeastern Europe—A Retrospective Analysis from Serbia  Mihajlo Jakovljević, MD, PhD,
Rutger Daems, PhD, Edith Maes, DBA, Christoph Glaetzer, Dipl, Kfm 
Cost-Effectiveness Analysis of a Screening Program for Breast Cancer in Vietnam  Lan Hoang Nguyen, Wongsa Laohasiriwong, John Frederick Stewart, Pamela.
Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,
Value in Health Regional Issues
Economic Evaluation of Bariatric Surgery in Mexico Using Discrete Event Simulation  Olivo Omar Zanela, MSc, Hermilo Arturo Cabra, MSc, Guillermo Meléndez,
Value in Health Regional Issues
Value in Health Regional Issues
Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore  Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,
What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.
Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia in Guatemala  Benjamin Cruz Rodriguez, MD, Sergio Leal, MD, Gonzalo Calvimontes,
Assessment of Effect of Diabetes on Health-Related Quality of Life in Patients with Coronary Artery Disease Using the EQ-5D Questionnaire  Bhavik Shah,
Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation.
Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD 
Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia 
Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD 
Omneya Mohamed, PhD, David H. Kreling, PhD 
Value in Health Regional Issues
The Economic Impact of Cigarette Smoking on the Poor in Jordan
Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project  Kyriakos Souliotis, PhD,
Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective  Bruno Salgado Riveros,
Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes  Maxwell O. Adibe,
Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters?  Chun-Ru Chien, MD, PhD, Ya-Chen Tina.
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan  Yoshie Onishi, MS,
The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System  Juan Guillermo Ariza, MD, MSc, Per-Olof Thuresson,
Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers  Valentina.
Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD 
Value in Health Regional Issues
Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea  Ji Haeng Heo, MS, Karen L.
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making  Roza Ismailovna Yagudina, PhD, Andrey Urievich.
Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Social Cost of Substance Abuse in Russia
Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD 
Economic Evaluation of Four Drug Administration Systems in Intensive Care Units in Colombia  Diego Rosselli, MD, MSc, Juan David Rueda, MD, María Daniela.
Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia  Vlado Jukic, MD, PhD, Miro Jakovljevic, MD, PhD, Igor Filipcic,
Victoria I. Ignatyeva, MPH, Johan L
A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina  Joaquín.
Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.
Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.
Economic Burden of Incident Unplanned Starts on Peritoneal Dialysis in a High Specialty Health Care Facility in Mexico City  Sergio O. Hdez Ordonez, MD,
Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD 
Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer  Thibaut Lizée, MD, Ethan Basch, MD, MSc, Pierre Trémolières,
Lars Oddershede, MMS, Jan J. Andreasen, MD, PhD, Barbara C
Presentation transcript:

Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María Galindo-Suárez, Pierre K. Alexandre, Erika Gabriela García-García, Emilio Muciño-Ortega, Guillermo Salinas- Escudero, Silvia Martínez-Valverde  Value in Health Regional Issues  Volume 1, Issue 2, Pages 211-217 (December 2012) DOI: 10.1016/j.vhri.2012.09.013 Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Model structure. Value in Health Regional Issues 2012 1, 211-217DOI: (10.1016/j.vhri.2012.09.013) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Scatter plot of 1000 incremental cost and incremental QALY for sirolimus versus tacrolimus in the prophylaxis of organ rejection in renal transplant recipients. QALY, quality-adjusted life-year. Value in Health Regional Issues 2012 1, 211-217DOI: (10.1016/j.vhri.2012.09.013) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Acceptability curve representing the probability that sirolimus (SIR) is cost-effective in comparison to tacrolimus (TAC) for different values of WTP for a QALY. QALY, quality-adjusted life-year; WTP, willingness to pay. Value in Health Regional Issues 2012 1, 211-217DOI: (10.1016/j.vhri.2012.09.013) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 4 Tornado diagram of the univariate sensitivity analysis showing the impact of individual input parameters on the ICER per QALY. ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; SIR, sirolimus; TAC, tacrolimus. Value in Health Regional Issues 2012 1, 211-217DOI: (10.1016/j.vhri.2012.09.013) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 5 Impact on (A) mortality, (B) the quality-adjusted life-year gained, and (C) dialysis risk from sirolimus or tacrolimus therapy. (D) Expected 20-year cumulative cost per patient. Value in Health Regional Issues 2012 1, 211-217DOI: (10.1016/j.vhri.2012.09.013) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.